Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Recommendation of “Hold” by Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned an average rating of “Hold” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $467.0833.

A number of analysts recently commented on the stock. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. BMO Capital Markets dropped their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research note on Friday, February 13th.

Medpace Stock Performance

Shares of Medpace stock opened at $429.11 on Wednesday. The firm has a fifty day moving average of $458.28 and a two-hundred day moving average of $516.59. The stock has a market capitalization of $12.26 billion, a price-to-earnings ratio of 26.97, a PEG ratio of 2.20 and a beta of 1.19. Medpace has a 52 week low of $291.28 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts forecast that Medpace will post 17.04 EPS for the current fiscal year.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Pomerantz, and others, reiterated reminders about the pending Medpace securities class action and the June 8 lead-plaintiff deadline. Article Title
• Neutral Sentiment: The class action centers on claims that Medpace overstated demand metrics and understated cancellations during the April 22, 2025 to February 9, 2026 class period. Article Title
• Negative Sentiment: The steady stream of litigation alerts adds uncertainty around potential settlement costs and legal distraction, which can pressure MEDP shares even without new operational news. Article Title

Insider Buying and Selling

In related news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 20.50% of the company’s stock.

Institutional Trading of Medpace

Hedge funds have recently added to or reduced their stakes in the business. Optiver Holding B.V. acquired a new stake in Medpace during the 3rd quarter worth $27,000. Geneos Wealth Management Inc. raised its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace during the 4th quarter worth $30,000. Elyxium Wealth LLC acquired a new stake in Medpace during the 4th quarter worth $30,000. Finally, Quarry LP acquired a new stake in Medpace during the 3rd quarter worth $35,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.